drugset / Trial / NCT04785794
Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
Phase 1
Completed
122 enrolled
FluGen Inc
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedSequentialQuadruple-blindBasic science
Summary
This is a randomized, double-blind, placebo-controlled Phase 1b study to evaluate safety and immunogenicity of the investigational Sing2016 M2SR H3N2 influenza vaccine delivered intranasally to a healthy adult population age 50 to 85 years.
Timeline
- Start
- 2021-06-30
- Primary completion
- 2021-11-30
- Completion
- 2021-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sing2016 M2SR H3N2 influenza vaccine | Vaccine | — | Intranasal |
Indications
No indication recorded.